Agomelatine in the treatment of anhedonia, somatic symptoms, and sexual dysfunction in major depressive disorder

被引:3
|
作者
Huang, Juan [1 ,2 ,3 ]
Xie, Xiao-Meng [1 ,2 ,3 ]
Lyu, Nan [1 ,2 ,3 ]
Fu, Bing-Bing [1 ,2 ,3 ]
Zhao, Qian [1 ,2 ,3 ]
Zhang, Ling [1 ,2 ,3 ]
Wang, Gang [1 ,2 ,3 ]
机构
[1] Capital Med Univ, Beijing Anding Hosp, Natl Clin Res Ctr Mental Disorders, Beijing Key Lab Mental Disorders, Beijing, Peoples R China
[2] Capital Med Univ, Beijing Anding Hosp, Natl Ctr Mental Disorders, Beijing, Peoples R China
[3] Capital Med Univ, Adv Innovat Ctr Human Brain Protect, Beijing, Peoples R China
来源
FRONTIERS IN PSYCHIATRY | 2023年 / 14卷
关键词
major depressive disorder; agomelatine; sexual dysfunction; anhedonia; somatic symptoms; QUALITY-OF-LIFE; STAR-ASTERISK-D; DOUBLE-BLIND; ANTIDEPRESSANT EFFICACY; REUPTAKE INHIBITORS; CHINESE VERSION; ANXIETY; RELIABILITY; FLUOXETINE; METAANALYSIS;
D O I
10.3389/fpsyt.2023.1115008
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
ObjectiveThis study evaluated the treatment outcomes of agomelatine on anhedonic state, anxiety/somatic symptoms, and sexual function in Chinese patients with major depressive disorder (MDD). MethodIn total, 93 adult patients with MDD were enrolled, and 68 of them were included in a prospective, open-label, multicenter clinical study. All patients received agomelatine monotherapy during a 9-week treatment phase. The effectiveness of the treatment was reflected by the improvement of anhedonia and somatic symptoms based on the 17-item Hamilton Depression Rating Scale (HAMD-17). In addition, the Arizona Sexual Dysfunction Scale (ASEX), Sheehan Disability Scale (SDS), and Short Form of Quality-of-Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q-SF) were administered to all participants at baseline and at the 3-, 6-, and 9-week follow-ups. ResultsAfter 9 weeks of treatment with agomelatine, the response and remission rates were 73.5% and 39.7%, respectively. Somatic symptoms significantly improved at week 9 (p < 0.001), and significant effects were also observed on the HAMD anhedonia items (p < 0.001). The patients exhibited lower levels of disease severity (the SDS score dropped from 15.52 +/- 4.7 to 7.09 +/- 5.62 at week 9; the ASEX score dropped from 21.89 +/- 4.06 to 16.19 +/- 4.79, p < 0.001) and higher levels of QOL (the Q-LES-Q-SF score dropped from 41.02 +/- 5.99 to 50.49 +/- 8.57, p < 0.001) during the follow-up. Furthermore, treatment with agomelatine improved depressive symptoms without causing serious adverse events. ConclusionThese analyses indicate that agomelatine is a treatment option for improving anhedonic status, anxiety/somatic symptoms, and sexual dysfunction in MDD patients.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] PHYSICAL ANHEDONIA IN MAJOR DEPRESSIVE DISORDER
    LOAS, G
    SALINAS, E
    GUELFI, JD
    SAMUELLAJEUNESSE, B
    JOURNAL OF AFFECTIVE DISORDERS, 1992, 25 (02) : 139 - 146
  • [22] EFFICACY OF THE ANTIDEPRESSANT AGOMELATINE FOR THE ANXIETY SYMPTOMS OF DEPRESSION IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER
    Stein, D. J.
    Castle, D. J.
    Kennedy, S. H.
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2012, 46 : 31 - 32
  • [23] Course of anhedonia and depressive symptoms in a population of depressed outpatients treated with agomelatine
    Llorca, P. M.
    Gourion, D.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2014, 24 : S468 - S468
  • [24] EFFICACY AND SAFETY OF AGOMELATINE IN TREATMENT OF MAJOR DEPRESSIVE DISORDER: A PILOT STUDY
    Nukala, Srikrishna
    Komaram, Ravi Babu
    Palla, Jayasree
    Murthy, K. S. N.
    INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH, 2016, 7 (08): : 3517 - 3521
  • [25] Major Depressive Disorder, sleep EEG and agomelatine
    Quera Salva, M.
    Vanier, B.
    Laredo, J.
    Moulin, C.
    Chapotot, F.
    Lofaso, F.
    Christian, G.
    SLEEP, 2006, 29 : A325 - A326
  • [26] Frequency of psychological and somatic symptoms in patients with major depressive disorder
    Chaudhry, Haroon Rashid
    Arshad, Nadia
    Javed, Faeza
    Asif, Aftab
    ASIAN JOURNAL OF PSYCHIATRY, 2010, 3 (03) : 152 - 154
  • [27] Somatic symptoms in outpatients with major depressive disorder treated with fluoxetine
    Denninger, JW
    Papakostas, GI
    Mahal, Y
    Merens, W
    Alpert, JE
    Nierenberg, AA
    Yeung, A
    Fava, M
    PSYCHOSOMATICS, 2006, 47 (04) : 348 - 352
  • [28] Placebo-controlled trial of agomelatine in the treatment of major depressive disorder
    Kennedy, SH
    Emsley, R
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2006, 16 (02) : 93 - 100
  • [29] Prevalence and association of somatic symptoms in patients with Major Depressive Disorder
    Vaccarino, Anthony L.
    Sills, Terrence L.
    Evans, Kenneth R.
    Kalali, Amir H.
    JOURNAL OF AFFECTIVE DISORDERS, 2008, 110 (03) : 270 - 276
  • [30] PHYSICAL ANHEDONIA AND SUBTYPES OF MAJOR DEPRESSIVE DISORDER
    LOAS, G
    PEROT, JM
    HARDY, P
    JOUVENT, R
    BOYER, P
    EUROPEAN PSYCHIATRY, 1994, 9 (06): : 304 - 306